A team led by Cabezas‑Caballero and colleagues reported engineered co‑signaling receptors that improve T‑cell targeting precision and reduce off‑target cross‑reactivity. The study describes synthetic receptor designs that tune costimulatory and coinhibitory signals to enhance antigen discrimination by adoptive T cells. The work offers a modular approach to lower toxicity risk and improve safety margins in next‑generation cell therapies, potentially enabling wider clinical utility for engineered T‑cell platforms.